Biosynex SA
PAR:ALBIO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.71
8.96
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALBIO stock under the Base Case scenario is 7.886 EUR. Compared to the current market price of 2.995 EUR, Biosynex SA is Undervalued by 62%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biosynex SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALBIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Biosynex SA
Balance Sheet Decomposition
Biosynex SA
Current Assets | 91.4m |
Cash & Short-Term Investments | 26.2m |
Receivables | 21.3m |
Other Current Assets | 43.9m |
Non-Current Assets | 150.4m |
Long-Term Investments | 2.9m |
PP&E | 16.1m |
Intangibles | 131.3m |
Current Liabilities | 51.4m |
Accounts Payable | 15.1m |
Accrued Liabilities | 9.7m |
Short-Term Debt | 239k |
Other Current Liabilities | 26.4m |
Non-Current Liabilities | 65.9m |
Long-Term Debt | 59.6m |
Other Non-Current Liabilities | 6.3m |
Earnings Waterfall
Biosynex SA
Revenue
|
93m
EUR
|
Cost of Revenue
|
-43.8m
EUR
|
Gross Profit
|
49.1m
EUR
|
Operating Expenses
|
-86.5m
EUR
|
Operating Income
|
-37.4m
EUR
|
Other Expenses
|
282k
EUR
|
Net Income
|
-37.1m
EUR
|
Free Cash Flow Analysis
Biosynex SA
EUR | |
Free Cash Flow | EUR |
ALBIO Profitability Score
Profitability Due Diligence
Biosynex SA's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Biosynex SA's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
ALBIO Solvency Score
Solvency Due Diligence
Biosynex SA's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Biosynex SA's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALBIO Price Targets Summary
Biosynex SA
According to Wall Street analysts, the average 1-year price target for ALBIO is 12.852 EUR with a low forecast of 12.726 EUR and a high forecast of 13.23 EUR.
Dividends
Current shareholder yield for ALBIO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALBIO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
Contact
IPO
Employees
Officers
The intrinsic value of one ALBIO stock under the Base Case scenario is 7.886 EUR.
Compared to the current market price of 2.995 EUR, Biosynex SA is Undervalued by 62%.